Regeneron Pharmaceuticals, Inc. and Adicet Bio, Inc. entered a collaboration and licensing agreement to develop next-gen immune cell therapeutics. The companies will engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens to enable the precise killing of tumor cells. The collaboration aims to generate multiple clinical candidates for various hematological and solid tumor cancers. Regeneron and Adi...